Other phase I/Ib clinical trials are evaluating the safety and tolerability of acalabrutinib in combination with either STAT3 inhibitor danvatirsen, ATR inhibitor AZD6738, anti-CD47 antibody Hu5F9-G4 plus anti-CD20 antibody rituximab, or bromodomain-containing protein 4 (BRD4) inhibitor AZD5153 in patients with r/r DLBCL (NCT03527147). The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.